Ichilov Hospital and VAXIL BIO, a company specializing in the development of innovative cancer treatment technologies and infectious diseases, have signed a collaboration to develop a potential peptide vaccine for the Corona COVID-19 virus.
The research will be led by Dr. David Hagin, director of the Allergy and Clinical Immunology Unit, through a unique pool of biological samples and the hospital’s advanced research infrastructure.
“The use of viral peptides (viral protein parts) for vaccination tries to circumvent the need to use the virus itself and actually exploits the fact that when a virus infects cells in the body, parts of the virus are shown on the cell. If an immune response develops for the major peptides, then the immune system will learn to attack and damage cells A virus-infected body will prevent further infection of cells, “explains Dr. Hagin.
“The use of a peptide signaling platform targeting infected cells, not just against the virus itself, is unique and promising. I see great potential in this innovative approach to create a corona virus vaccine. We share VAXIL’s vision to create a vaccine quickly, for the benefit of many populations around the world.”
“This collaboration agreement is a key milestone in the preclinical phase of research to find a candidate for the 19 vaccine COVID, and paves the way for clinical research during 2020,” explains David Goren, chairman and CEO of VAXIL, Ichilov Medical is a leading hospital, and is at the forefront of the fight against the corona epidemic in Israel and around the world. We look forward to working with Dr. Hagin, and the medical and research teams who partner for the important cause. ”